Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 7/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | LIPE | Q05469 | 1/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29067955 | 0.82 | MAPK14 (0.48) | MAPK14HTTSMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL28378443 | 0.79 | MAPK14 (0.42) | MAPK14HTTSMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL17128962 | 0.79 | MAPK14 (0.42) | MAPK14HTTSMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL9870348 | 0.78 | SGMS2 (0.44) | MAPK14HTTSMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL10671051 | 0.78 | MAPK14 (0.47) | MAPK14HTTSMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL30982580 | 0.78 | TLR4 (0.45) | MAPK14HTTSMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL30982987 | 0.78 | TLR4 (0.45) | MAPK14HTTSMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL30982887 | 0.78 | TLR4 (0.45) | MAPK14HTTSMN1; SMN2MEN1ALDH1A1 | |
| Propionic Acid SCHEMBL28565391 | 0.76 | MAPK14 (0.42) | MAPK14HTTSMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL16744408 | 0.75 | MAPT (0.47) | MAPK14HTTSMN1; SMN2MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119176807-A | Alpha-hydroxy ketone nitrogen-containing fused ring compound and application thereof | 北京英飞智药科技有限公司 | 2024-12-24 | — | — | CN | disclosed |
| EP-2134688-B1 | FLUORINATED DERIVATIVES OF DEFERIPRONE | APOTEX TECHNOLOGIES INC (CA) | 2016-10-05 | — | — | EP | disclosed |
| US-8673943-B2 | Fluorinated derivatives of deferiprone | APOTEX TECHNOLOGIES INC. (CA) | 2014-03-18 | — | — | US | disclosed |
| US-20130252935-A1 | Monobactams | PFIZER INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20120302542-A1 | MONOBACTAMS | PFIZER INC | 2012-11-29 | — | — | US | disclosed |
| US-20120095061-A1 | Fluorinated Derivatives of Deferiprone | APOTEX TECHNOLOGIES INC. (CA) | 2012-04-19 | — | — | US | disclosed |
| US-8026261-B2 | neurodegenerative diseases; to remove free iron or iron accumulation in neural tissues; iron chelators; improved chemical stability, penetration through blood brain barrier; reacting 3-hydroxy-4-pyridinone/3-hydroxy-4-pyranone derivatives; 1-cyclopropyl-2-difluoromethyl-5-hydroxy-1H-pyridin-4-one | APOTEX TECHNOLOGIES INC. (CA) | 2011-09-27 | — | — | US | disclosed |
| EP-2134688-A1 | FLUORINATED DERIVATIVES OF DEFERIPRONE | Apotex Technologies Inc. (CA) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008116301-A1 | FLUORINATED DERIVATIVES OF DEFERIPRONE | APOTEX TECHNOLOGIES INC. (CA) | 2008-10-02 | — | — | WO | disclosed |
| US-20080242706-A1 | Fluorinated derivatives of deferiprone | APOTEX TECHNOLOGIES INC. | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242706-A1 | Fluorinated derivatives of deferiprone | SLC40A1, TFRC, FECH | MAPK14 3642/4885HTT 140/4885SMN1; SMN2 72/4885 |
| US-20130252935-A1 | Monobactams | MGAM, MGAM2, BPGM | MAPK14 3727/4885HTT 4274/4885SMN1; SMN2 4574/4885 |
| US-20120095061-A1 | Fluorinated Derivatives of Deferiprone | SLC40A1, TFRC, FECH | MAPK14 3642/4885HTT 140/4885SMN1; SMN2 72/4885 |
| US-20120302542-A1 | MONOBACTAMS | MGAM, MGAM2, BPGM | MAPK14 3727/4885HTT 4274/4885SMN1; SMN2 4574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.